GSK-LSD1 2HCL
Modify Date: 2025-08-31 19:47:30
GSK-LSD1 2HCL structure
|
Common Name | GSK-LSD1 2HCL | ||
|---|---|---|---|---|
| CAS Number | 1431368-48-7 | Molecular Weight | 216.322 | |
| Density | 1.1±0.1 g/cm3 | Boiling Point | 347.4±42.0 °C at 760 mmHg | |
| Molecular Formula | C14H20N2 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | 206.0±19.7 °C | |
Use of GSK-LSD1 2HCLGSK-LSD1 is a LSD1 inhibitor. GSK-LSD1 reduces food intake and body weight, and improves insulin sensitivity and glycemic control in mouse models of obesity. GSK-LSD1 also ameliorates NAFLD. GSK-LSD1 inhibits SARS-CoV-2-triggered cytokine release in COVID-19 PBMCs. GSK-LSD1 also inhibits cancer growth and metastasis[1][2][3]. |
| Name | N-[(1R,2S)-2-Phenylcyclopropyl]-4-piperidinamine |
|---|---|
| Synonym | More Synonyms |
| Description | GSK-LSD1 is a LSD1 inhibitor. GSK-LSD1 reduces food intake and body weight, and improves insulin sensitivity and glycemic control in mouse models of obesity. GSK-LSD1 also ameliorates NAFLD. GSK-LSD1 inhibits SARS-CoV-2-triggered cytokine release in COVID-19 PBMCs. GSK-LSD1 also inhibits cancer growth and metastasis[1][2][3]. |
|---|---|
| Related Catalog | |
| References |
| Density | 1.1±0.1 g/cm3 |
|---|---|
| Boiling Point | 347.4±42.0 °C at 760 mmHg |
| Molecular Formula | C14H20N2 |
| Molecular Weight | 216.322 |
| Flash Point | 206.0±19.7 °C |
| Exact Mass | 216.162643 |
| LogP | 1.63 |
| Appearance of Characters | white to beige |
| Vapour Pressure | 0.0±0.8 mmHg at 25°C |
| Index of Refraction | 1.580 |
| Storage condition | 2-8°C |
| Water Solubility | H2O: soluble20mg/mL, clear |
| N-[(1R,2S)-2-Phenylcyclopropyl]-4-piperidinamine |
| 4-Piperidinamine, N-[(1R,2S)-2-phenylcyclopropyl]- |
| GSK-LSD1 2HCL |
| GSK-LSD1 (hydrochloride) |
| LSD1 inhibitor |